ProSomnus® Sleep Technologies to Present Three Posters at 2022 American Academy of Dental Sleep Medicine Annual Meeting

2 years ago

Company to showcase efficacy of its precision Oral Appliance Therapy devices in treating Obstructive Sleep ApneaSAN FRANCISCO, April 20, 2022 (GLOBE…

Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

2 years ago

Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE)…

Lowell Farms Inc. Becomes Exclusive Distributor of Zippo Products for California Cannabis Dispensaries

2 years ago

Groundbreaking partnership includes debut of Lowell Farms-branded lighters within the Zippo portfolioSALINAS, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- In a…

OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

2 years ago

New services include pathogen identification, microbiome profiling and rapid turnaround sequencing of clinical isolatesROCKVILLE, Md., April 20, 2022 (GLOBE NEWSWIRE)…

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

2 years ago

*** David Reardon, Luigi Naldini, Brad Loncar ***MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science…

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

2 years ago

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57…

Reduction of share capital

2 years ago

Please read the full announcement in the attached PDF Attachment 2022_12_Reduction_of_share_capital

Clover’s Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease

2 years ago

--94% cumulative protective effect against COVID-19 in previously-infected individuals that subsequently received Clover’s COVID-19 vaccine candidate-- --First and only COVID-19…

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

2 years ago

- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) --…

Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience

2 years ago

LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified…